← Leaderboards
Mireille Jacobson
Rand Corporation
$3,896,655
Attributed
$4,443,458
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,937,570 · 5
AHRQ$1,505,888 · 2
By mechanism
R01$2,108,412 · 3
R21$922,319 · 2
P30$793,101 · 1
R61$619,626 · 1
Top collaborators
- Silvia Helena Barcellos2 shared
- Doris Patricia Molina-Henry2 shared
Most similar at Rand Corporation
Same institution · by research overlap
- Julie M Zissimopoulos$11,179,780
- Alan Leslie Gustman$3,256,929
- Ian Douglass Coulter$14,404,308
- Dana P Goldman$26,931,376
- Arie Kapteyn$101,412,267
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposAffectMedicareRaceSurveysMedicaidCostBehavioralReportingMedicalLow IncomeUniversitiesPoliciesLinkFutureCaregiversHealthcareFundingHealth DisparityMedicare ClaimBaseDementiaCaliforniaElderly
Grant awards (15)
Cost and Non-Cost Barriers to Use of Novel AD Therapeutics among Older Adults$308,285
R61 · FY2025 · AG · contact PI
University of Southern California Alzheimerâs Disease (AD) and Alzheimerâs Disease-Related Dementias (ADRD) Resource Center for Minority Aging Research (USC AD/ADRD RCMAR)$267,668
P30 · FY2025 · AG · contact PI
Cost and Non-Cost Barriers to Use of Novel AD Therapeutics among Older Hispanic or Latino Adults$311,341
R61 · FY2024 · AG · contact PI
University of Southern California Alzheimerâs Disease (AD) and Alzheimerâs Disease-Related Dementias (ADRD) Resource Center for Minority Aging Research (USC AD/ADRD RCMAR)$267,668
P30 · FY2024 · AG · contact PI
University of Southern California Alzheimerâs Disease (AD) and Alzheimerâs Disease-Related Dementias (ADRD) Resource Center for Minority Aging Research (USC AD/ADRD RCMAR)$257,765
P30 · FY2023 · AG · contact PI
Medicaid versus Private Coverage for Low-Income Families: What are the Tradeoffs between Cost-Sharing and Access to Care$276,500
R01 · FY2021 · HS · contact PI
Medicaid versus Private Coverage for Low-Income Families: What are the Tradeoffs between Cost-Sharing and Access to Care$265,253
R01 · FY2020 · HS · contact PI
Medicaid versus Private Coverage for Low-Income Families: What are the Tradeoffs between Cost-Sharing and Access to Care$292,750
R01 · FY2019 · HS · contact PI
Did the Medicare Modernization Act Cause Oncology Drug Shortages$671,385
R01 · FY2014 · HS · contact PI
Health Insurance, Non-Deferrable Health Events and Financial Risk$227,980
R21 · FY2014 · AG
The Welfare Consequences of Oncology Drug Shortages$206,077
R21 · FY2014 · CA · contact PI
Health Insurance, Non-Deferrable Health Events and Financial Risk$246,000
R21 · FY2013 · AG
The Welfare Consequences of Oncology Drug Shortages$242,262
R21 · FY2013 · CA · contact PI
Are Disparities in Cancer Chemotherapy Treatment Affected by Medicare Reimburseme$283,311
R01 · FY2011 · CA · contact PI
Are Disparities in Cancer Chemotherapy Treatment Affected by Medicare Reimburseme$319,213
R01 · FY2010 · CA · contact PI